PBE241220P61000
- 0.00
- 0.000.00%
Invesco Biotechnology & Geno Funds Newsroom
Wednesday Ends With Index Decline | Wall Street Today
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Exelixis Provides Regulatory Update Related To Supplemental New Drug Application For Cabozantinib; Alliance For Clinical Trials In Oncology Independent Data And Safety Monitoring Board Recommends Trial Enrollment To Be Stopped
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Amgen's weight loss drug has a remarkable 20% reduction effect, but with high side effects, causing the stock price to plummet by 12.3% at one point!
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Amgen Decline on MariTide Data Could Be Due to Lack of More Details
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
4 Stocks to Watch on Tuesday: AMGN, BBY and More
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
How Is The Market Feeling About United Therapeutics?
Amgen Shares Are Trading Lower Following the Results of Its Phase 2 Study With MariTide in Obesity.
Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG